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28Mortality in patients with premature lower
extremity atherosclerosis
Hamza Rana, MD,a Jeanette S. Andrews, MS,b Billy G. Chacko, MD,c Kimberley J. Hansen, MD,c and
Pavel J. Levy, MD,c New York, NY; and Winston-Salem, NC
Objective: Lower extremity peripheral artery disease occurs mostly in the elderly and is associated with high mortality.
Limited data are available regarding long-term mortality in patients with premature lower extremity atherosclerosis
(PLEA). Our objective was to determine the all-cause mortality and its predictors in younger PLEA patients.
Methods: We studied patients with severe PLEA who were <55 years of age at diagnosis and treated at a single academic
vascular center between 1998 and 2010. Data were collected prospectively at the initial evaluation for vascular care.
National Death Index and hospital records were used to determine all-cause mortality. Demographic and clinical char-
acteristics were summarized using count (%), mean (standard deviation), or median (interquartile range), and associations
with aspirin use were tested using c2 test, t-test, or Wilcoxon test. Survival times were estimated using Kaplan-Meier
estimates, and associations with covariates were tested using simple and multivariable Cox proportional hazards models.
Results: A total of 564 patients were analyzed (46% female; 20% nonwhite; mean age 49.4 [6.4] years). Ninety-ﬁve percent
of patients had $2 cardiovascular risk factors, 31% had coronary artery disease (CAD), and 10% had a history of cancer.
During median follow-up of 5.6 years (interquartile range, 2.3-8.3 years), 108 deaths (19%) were recorded. Two-year
estimated mortality (standard error) was 6% (0.01), and 5-year estimated mortality was 16% (0.02). In univariate
regression analysis, patient age (P[ .04), prior amputation (P < .01), history of cancer (P[ .03), and established CAD
(P [ .04) were associated with increased risk of mortality. Aspirin use and lipid-lowering therapy at the time of ﬁrst
evaluation were associated with improved survival (P < .01 and P[ .02, respectively). A multivariable Cox proportional
hazards model identiﬁed age (hazard ratio [HR] for 5-year increase, 1.17; 95% CI, 1.01-1.36; P[ .04), prior amputation
(HR, 1.99; 95% CI, 1.18-3.34; P[ .01), history of cancer (HR, 2.35; 95% CI, 1.36-4.07; P < .01), and CAD (HR, 1.76;
95% CI, 1.16-2.67; P < .01) as independent predictors of mortality in patients with PLEA. Importantly, history of aspirin
use had a signiﬁcant protective effect (HR, 0.45; 95% CI, 0.30-0.69; P < .01). The impact of lipid-lowering therapy was
no longer signiﬁcant in multivariable modeling.
Conclusions: Patients with PLEA demonstrate high all-cause mortality. No traditional cardiovascular risk factors pre-
dicted mortality. Aspirin therapy at the time of ﬁrst evaluation was a signiﬁcant and independent predictor of improved
survival in patients with PLEA. (J Vasc Surg 2013;57:28-36.)Peripheral artery disease (PAD) is a major health care
problem affecting approximately 8 to 12 million Ameri-
cans.1 PAD is generally considered to be a disease of older
individuals and is frequently diagnosed in the sixth,
seventh, and eighth decades of life. Therefore, the vast
majority of epidemiologic and clinical PAD studies in the
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://dx.doi.org/10.1016/j.jvs.2012.07.041However, with the growing awareness of early occurrence
of systemic advanced atherosclerotic changes, it has been
increasingly recognized that a small but clinically signiﬁcant
number of young adults are afﬂicted prematurely.2
Previous studies have reported that young adults account
for 1% to 7% of all cases of PAD. These estimates were
based on relatively small studies and varied by the age
criteria used.3-7
Atherosclerotic arterial occlusive disease is recognized
as the most common cause of lower extremity ischemia
in young adults.8-11 Unlike the relatively slow progression
of peripheral atherosclerosis in the elderly, premature lower
extremity atherosclerosis (PLEA) in young patients has
been characterized by rapid progression of clinical
disease9,12 and the presence of severe symptoms at diag-
nosis.5,8 It has been reported to be associated with high
amputation rates8,12,13 and death.6,13
Patients with PAD typically have heightened morbidity
and mortality, attributed in part to their advanced age and
high prevalence of systemic clinical atherosclerosis. Early
and late mortality rates among patients with PLEA have
been reported.4,6,10 Long-term mortality rates range from
17%4 to 32%6 over 3 to 5 years in studies reported more
than 3 decades ago. These studies suffer from small sample
size and include highly selected patient populations; thus,
they lack generalizability. Furthermore, data provided no
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patients with PLEA.
The aim of this study was to determine all-cause
mortality and its predictors, and the causes of deaths in
a large cohort of patients with PLEA. In this study,
PLEA was deﬁned as the presence of severe symptoms of
PAD conﬁrmed by either noninvasive or angiographic
studies in patients 55 years or younger at the time of
diagnosis of PAD.
METHODS
Five hundred sixty-four patients with severe PLEA
treated at our academic tertiary referral vascular center
at Wake Forest Baptist Medical Center between January
1998 and May 2010 were studied. The study included
patients with symptomatic PAD conﬁrmed by an ankle-
brachial index (ABI) <0.9 with or without exercise tread-
mill test or angiographic evidence of severe (ie, >70%)
atherosclerotic occlusive disease in large arteries of the
lower extremities or a history of prior lower extremity
revascularizations or amputations. All patients included
in the study had been diagnosed with lower extremity
atherosclerosis before age 55 years and were treated by
a team of vascular surgery and vascular medicine special-
ists. Data were collected prospectively at the initial evalu-
ation for vascular care and were entered in the database.
Patients with end-stage renal disease requiring dialysis,
aneurysmal disease and related symptoms, arterial trauma,
diabetic foot without proximal PAD, small-vessel disease
of the lower extremity or other nonatherosclerotic causes
of lower extremity arterial occlusive disease, or incom-
plete/missing data were excluded from the study. The
study protocol was approved by the hospital’s Institu-
tional Review Board.
The clinical information that was obtained prospec-
tively and used in the data analyses included demographic
characteristics and cardiovascular risk factors, such as
hypertension (deﬁned as systolic blood pressure >140
mm Hg, diastolic blood pressure >90 mm Hg, or both;
or use of antihypertensive medications), diabetes mellitus
(use of antidiabetic treatment or documented presence of
diabetes), hyperlipidemia (use of lipid-lowering therapy),
smoking (current, former, pack years), and family history
of coronary artery disease (CAD), cerebrovascular disease
(CeVD), or PAD. Previous CAD was considered if the
patient had a history of myocardial infarction, acute coro-
nary syndrome, or angina pectoris, and/or percutaneous
coronary intervention, coronary artery bypass graft, or
history of positive stress test conﬁrmed by coronary angio-
gram. Previous CeVD was considered if the patient had
a history of cerebrovascular accident, transient ischemic
attack, carotid endarterectomy, or presence of asymptom-
atic, >60% stenosis of the internal carotid artery.
Other predictor variables included use of medication
such as aspirin, lipid-lowering drugs, and angiotensin-
converting enzyme (ACE) inhibitors; age at diagnosis of
PAD; clinical severity of PAD at diagnosis of PAD (Fon-
taine classes 1-4); prior lower extremity revascularizationsor amputations; presence of systemic disease or cancer;
and family history of early malignancy. Systemic disease
was considered if the patient had a documented history of
HIV infection, connective tissue disease (systemic lupus
erythematous, scleroderma, rheumatoid arthritis), or
inﬂammatory bowel disease. All of these variables were
identiﬁed at the initial evaluation for vascular care and
were based on documentation in the hospital medical
records or outside medical records and on patient/family
self-report. Data on ABI were not abstracted for the
following reasons: ﬁrst, because the majority of patients in
our cohort were diagnosed outside of our institution and
data on ABI at their diagnosis typically were not available;
and second, because the large population of patients
already had revascularizations for PAD, ABI at the time of
initial evaluation might not correlate with severity of PAD.
The primary outcome was all-cause mortality.
Mortality data were obtained for patients through 2010
by using the National Death Index (NDI) provided by
the National Center for Health Statistics and hospital
records. Use of the NDI allowed us to retrieve data on
follow-up mortality for patients through December 2008.
Information for subsequent mortality was obtained via
electronic medical records at our hospital for the years
2009 and 2010. Causes of death were obtained from the
NDI database and/or hospital medical records. No addi-
tional contact was made with the patients or their family
members in order to obtain additional survival information.
Statistical analysis. Demographic and clinical charac-
teristics were summarized using count (%), mean (standard
deviation), or median (interquartile range [IQR]), and
associations with aspirin use were tested using c2 test, t-
test, or Wilcoxon test. Survival times were evaluated using
Kaplan-Meier estimates, and associations with covariates
were tested using simple and multivariable Cox propor-
tional hazards models. Multivariable models were devel-
oped using stepwise variable selection (P < .05 to enter the
model and P < .05 to stay). Multivariable analysis included
(1) demographics (age, sex, and race); (2) atherosclerotic
risk factors (hypertension, diabetes mellitus, hyperlipid-
emia, current smoking, and any family history of athero-
sclerotic cardiovascular disease), pack years, age at
diagnosis of atherosclerotic cardiovascular disease; (3)
antiplatelet therapy (aspirin), lipid-lowering therapy, use of
ACE inhibitor; (4) prior history of CAD and CeVD, prior
PAD intervention, prior history of amputation, systemic
disease, or cancer; (5) and interval between the age at ﬁrst
diagnosis of cardiovascular disease (CAD, CeVD, and
PAD) the ﬁrst evaluation in our center.
Proportional hazards model results are reported as
hazard ratio (HR) with corresponding 95% CI and
P values. Time to event was calculated as the number of
days from initial visit at our vascular center to date of death.
Patients were censored if no deaths occurred by the end of
the follow-up period (December 31, 2010) or the date of
last contact. Observations with censoring times longer
than 10 years were truncated at 10 years. For all analyses,
a two-sided value of P < .05 was considered statistically
Table I. Baseline characteristics
Variable N Total (N ¼ 564) Died (N ¼ 108) Alive (N ¼ 456)
Age at ﬁrst evaluation, mean (SD), years 564 49.4 (6.4) 50.1 (5.7) 49.2 (6.60)
Age at diagnosis of atherosclerotic cardiovascular
disease, mean (SD), years
564 45.4 (6.9) 45.1 (6.9) 45.5 (6.9)
Age at diagnosis of peripheral artery disease, mean (SD), years 564 46.6 (6.9) 46.7 (6.9) 46.6 (6.8)
Interval from ﬁrst diagnosis to initial evaluation, yearsa 555 2 (0, 6) 2 (0, 9) 2 (0, 5)
Female gender 564 259 (45.9) 44 (40.7) 215 (47.2)
Nonwhite race/ethnicity 564 111 (19.7) 26 (24.1) 85 (18.6)
Current smoker 563 403 (71.6) 75 (69.4) 328 (72.1)
Smoking, mean (SD), pack-years 545 46.9 (26.1) 50.8 (28.8) 46.0 (25.4)
Hypertension 563 359 (63.8) 66 (61.1) 293 (64.4)
Hyperlipidemia 564 321 (56.9) 59 (54.6) 262 (57.5)
Diabetes mellitus 562 143 (25.4) 34 (31.5) 109 (24.0)
Any family history of atherosclerotic cardiovascular disease 545 433 (79.5) 92 (87.6) 341 (77.5)
Prior coronary artery disease 560 174 (31.1) 44 (40.7) 130 (28.8)
Prior cerebrovascular disease 564 148 (26.2) 35 (32.4) 113 (24.8)
Aspirin use 561 413 (73.6) 67 (62.0) 346 (76.4)
Lipid-lowering therapy 562 414 (73.7) 68 (63.0) 346 (76.2)
Angiotensin-converting enzyme inhibitor use 560 245 (43.8) 45 (41.7) 200 (44.3)
Prior surgery for peripheral artery disease 563 394 (70.0) 81 (75.0) 313 (68.8)
Prior amputation 546 53 (9.7) 18 (17.0) 35 (8.0)
Fontaine class 536
1 11 (2.1) 1 (1.0) 10 (2.3)
2 378 (70.5) 61 (61.6) 317 (72.5)
3 137 (25.6) 36 (36.4) 101 (23.1)
4 10 (1.9) 1 (1.0) 9 (2.1)
Systemic disease 558 65 (11.7) 14 (13.0) 51 (11.3)
Cancer 560 57 (10.2) 17 (15.7) 40 (8.9)
Any family history of early malignancy 533 111 (20.8) 17 (16.7) 94 (21.8)
SD, Standard deviation.
Values are given as N (%) or median (Q1, Q3) unless otherwise indicated.
aInterval from time of ﬁrst diagnosis (coronary artery disease, cerebrovascular disease, or peripheral artery disease) to our ﬁrst evaluation.
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(version 9.2; SAS Institute Inc, Cary, NC).
RESULTS
Patient characteristics. A total of 564 patients were
analyzed (46% female; 20% nonwhite; mean age 49.4
[6.4] years at time of ﬁrst evaluation at our vascular center),
including 246 patients (43.6%) younger than 50 years.
Baseline characteristics of all patients with PLEA are given
in Table I. Mean age at the time of diagnosis of PAD was
46.6 (6.9) years, with median IQR interval between time
of ﬁrst diagnosis (CAD, CeVD, or PAD) and our ﬁrst
evaluation of 2 (0, 6) years. Ninety-ﬁve percent of patients
had $2 cardiovascular risk factors, with smoking (current
in 72%) and family history of cardiovascular disease (79%)
being the most prevalent. Concomitant clinical conditions
included established CAD (31%), systemic disease (12%),
and cancer (10%).
Follow-up mortality and predictors. Over a median
follow-up period of 5.6 years (IQR, 2.3-8.3 years), 108
deaths were identiﬁed for a mortality rate of 19%. Unad-
justed regression analysis of all-cause mortality is given
in Table II. Patient age (P ¼ .038), prior amputation
(P ¼ .005), history of cancer (P ¼ .026), and established
CAD (P ¼ .037) were associated with increased risk of
mortality. Aspirin use and lipid-lowering therapy at the
time of ﬁrst evaluation were associated with improvedsurvival (P ¼ .004 and P ¼ .016, respectively). The
multivariable Cox proportional hazards model identiﬁed
age (HR for 5-year increase, 1.17; 95% CI, 1.01-1.36; P ¼
.040), prior amputation (HR, 1.99; 95% CI, 1.18-3.34;
P ¼ .010), history of cancer (HR, 2.35; 95% CI,
1.36-4.07; P ¼ .002), and CAD (HR, 1.76; 95% CI,
1.16-2.67; P ¼ .008) as independent predictors of
mortality in patients with PLEA. Importantly, history of
aspirin use had a signiﬁcant protective effect (HR, 0.45;
95% CI, 0.30-0.69; P < .001). Lipid-lowering therapy was
not independently associated with mortality in the multi-
variable model.
In a separate analysis, a subset of patients without
a history of cancer yielded minor differences from the
main model. In the unadjusted regression analysis of all-
cause mortality, diabetes (P < .05) was also a signiﬁcant
predictor of mortality. However, lipid-lowering therapy at
the time of ﬁrst evaluation was not signiﬁcantly associated
with improved survival in this subset. The multivariable
Cox proportional hazards model did not identify CAD as
an independent predictor of mortality in PLEA patients
without cancer.
Because aspirin use at initial evaluation had such
a robust effect on lowering mortality, the characteristics
of PLEA patients on aspirin vs those with no aspirin at
the time of ﬁrst evaluation were compared (Table III).
Overall, 74% of PLEA patients were on aspirin at the
Table II. Cox proportional hazards regression analysis of all-cause mortality
Variable
Unadjusted models Multivariable modela
N Hazard ratio (95% CI) P value Hazard ratio (95% CI) P value
Age at ﬁrst evaluation (5-year increase) 564 1.17 (1.01, 1.36) .038 1.17 (1.01, 1.36) .040
Age at diagnosis of atherosclerotic cardiovascular
disease (1-year increase)
564 1.01 (0.98, 1.03) .636 d d
Interval from ﬁrst diagnosis to initial evaluation
(1-year increase)
555 1.03 (1.00, 1.07) .043 d d
Female gender 564 0.82 (0.56, 1.20) .304 d d
Nonwhite race/ethnicity 564 1.22 (0.78, 1.89) .385 d d
Current smoker 563 1.06 (0.70, 1.60) .779 d d
Pack-years (1 pack-year increase) 545 1.00 (1.00, 1.01) .356 d d
Hypertension 563 1.10 (0.75, 1.62) .629 d d
Hyperlipidemia 564 0.96 (0.65, 1.40) .813 d d
Diabetes mellitus 562 1.44 (0.96, 2.17) .077 d d
Any family history of atherosclerotic cardiovascular
disease
545 1.62 (0.91, 2.90) .103 d d
Prior coronary artery disease 560 1.50 (1.03, 2.21) .037 1.76 (1.16, 2.67) .008
Prior cerebrovascular disease 564 1.28 (0.85, 1.91) .232 d d
Aspirin use 561 0.56 (0.38, 0.83) .004 0.45 (0.30, 0.69) <.001
Lipid-lowering therapy 562 0.62 (0.42, 0.91) .016 d d
Angiotensin-converting enzyme inhibitor use 560 0.90 (0.61, 1.31) .574 d d
Prior surgery for peripheral artery disease 563 1.15 (0.74, 1.78) .525 d d
Prior amputation 546 2.07 (1.24, 3.43) .005 1.99 (1.18, 3.34) .010
Systemic disease 558 1.12 (0.64, 1.96) .696 d d
Cancer 560 1.81 (1.07, 3.03) .026 2.35 (1.36, 4.07) .002
Fontaine class 3 or 4 536 1.68 (1.11, 2.52) .0130 d d
aMultivariable model adjusts for covariates selected using stepwise procedure: candidate covariate list includes all variables in the table.
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cantly higher history of CAD and CeVD, and greater
proportion of them were prescribed lipid-lowering therapy
and ACE inhibitors. However, in our multivariable anal-
ysis, both lipid-lowering therapy and ACE inhibitors were
not independently associated with all-cause mortality.
Patients with prior amputation and PAD Fontaine classes
3 and 4 were signiﬁcantly less likely to be on aspirin at
the time of initial evaluation.
Five-year mortality and disease status. Figure 1
shows the Kaplan-Meier estimates for all-cause mortality
for the entire cohort of patients. The overall estimated
mortality (standard error) at 2, 5, and 10 years of follow-up
was 6% (0.01), 16% (0.02), and 32% (0.03), respectively.
Figure 2 shows survival stratiﬁed by history of CAD (Fig 2,
A), history of aspirin use (Fig 2, B), history of cancer (Fig
2, C), and age <50 or $50 years (Fig 2, D), and shows
Kaplan-Meier 5-year survival estimates and log-rank test
results for each. PLEA patients not on aspirin had a signif-
icantly higher mortality than did patients on aspirin, and
PLEA patients with a history of CAD or cancer also had
a signiﬁcantly higher mortality compared with patients
without CAD and cancer, respectively. However, on
further analysis after excluding patients with cancer or
systemic diseases, the mortality of PLEA patients with
a history of CAD was not signiﬁcantly higher than that
of patients without CAD at initial evaluation (P ¼ .094,
log-rank test; Fig 3).
Causes of death. Among the 108 PLEA patients who
died during follow-up, 66 (61.1%) died of cardiovascularcauses, 17 died of cancer, and 21 died of other causes
(Table IV). No cause of death was available for four
patients. Eighty-nine patients (82.4%) had either prior
CAD and/or CeVD at ﬁrst evaluation, or developed
cardiovascular events during the follow-up period accord-
ing to hospital records. Importantly, 92 (85.2%) had
documented cardiovascular disease and/or malignancy
before death.
DISCUSSION
To our knowledge, the present study represents the
analysis of the largest and most diverse (as related to gender
and race) cohort of patients with clinical PLEA and
provides data on mortality and its predictors. The study
population was similar to previously reported populations
in smaller series with respect to traditional risk factors14,15
and prior history of established CAD.11,15 Our ﬁndings
conﬁrmed high follow-up mortality in PLEA patients and
demonstrated its strong independent association with
several clinical characteristics that were present at baseline,
such as prior history of CAD, need for amputation, and
known malignancy. Patients on aspirin therapy at the
time of ﬁrst evaluation had signiﬁcantly improved survival.
Importantly, neither gender and race, nor any of the tradi-
tional risk factors, were predictive of long-term mortality.
All of our study patients had advanced PLEA resulting
in clinically severe PAD, with a large proportion of patients
undergoing major revascularizations prior to their ﬁrst eval-
uation in our vascular center. According to previously pub-
lished data on older individuals, PAD was uniformly
Table III. Characteristics of patients on aspirin at initial evaluation vs those not on aspirin
Variable
On aspirin at initial evaluation
P valuea
No (N ¼ 148) Yes (N ¼ 413)
Age at ﬁrst evaluation, mean (SD), years 48.4 (7.0) 49.7 (6.2) .031
Age at diagnosis of peripheral artery disease, mean (SD), years 45.4 (7.4) 47.1 (6.6) .011
Interval from ﬁrst diagnosis to initial evaluation, years 1 (0, 5) 2 (0, 6) .087
Female gender 79 (53.4) 178 (43.1) .031
Nonwhite race/ethnicity 24 (16.2) 86 (20.8) .226
Current smoker 109 (73.7) 292 (70.9) .521
Hypertension 83 (56.5) 274 (66.3) .032
Hyperlipidemia 61 (41.2) 259 (62.7) <.001
Diabetes mellitus 34 (23.0) 109 (26.5) .396
Any family history of atherosclerotic cardiovascular disease 120 (85.1) 310 (77.3) .049
Prior coronary artery disease 21 (14.3) 153 (37.3) <.001
Prior cerebrovascular disease 26 (17.6) 120 (29.1) .006
Lipid-lowering therapy 80 (54.1) 333 (80.8) <.001
Angiotensin-converting enzyme inhibitor use 49 (33.1) 196 (47.7) .002
Prior surgery for peripheral artery disease 112 (75.7) 279 (67.7) .071
Prior amputation 21 (14.5) 32 (8.0) .025
Fontaine class 3 or 4 50 (36.5) 95 (24.0) .005
Systemic disease 21 (14.2) 43 (10.6) .237
Cancer 14 (9.5) 43 (10.5) .717
SD, Standard deviation.
aP value from c2 test (categorical), t-test (continuous), or Wilcoxon test (interval from ﬁrst diagnosis to evaluation).
Fig 1. Kaplan-Meier survival estimates for all-cause mortality
(overall). SE, Standard error.
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compared with those without PAD. An early study by
Criqui et al16 reported a 15-fold increase in mortality due
to cardiovascular disease in patients with severe and symp-
tomatic large-vessel PAD. Using the nationally representa-
tive National Health and Nutrition Examination Survey
(NHANES) database, Pande et al17 recently identiﬁed
647 PAD subjects (mean age 67.8 years) with weighted
mortality rate of 22.6% over mean follow-up of 4.4 years.
In our study, 19% of PLEA patients died during medianfollow-up of 5.6 years. In one of the ﬁrst large series pub-
lished in 1970, Najaﬁ et al6 reported 32% mortality over
a 10-year period in 59 patients aged 32 to 45 years who
underwent aortoiliac reconstructions between 1953 and
1968. Our results are consistent with previous studies of
younger adults published almost 2 decades ago that re-
ported mortality rates between 17% and 20%.4,13,18 Hence,
this may be indicative of the lack of improvement in long-
term mortality in patients with premature PAD over the
past several decades. The reported mortality rate certainly
is higher than the expected <2% mortality according to
the United States National Center for Health Statistics vital
statistics.15 Additional analysis of our data showed no
signiﬁcant difference in 5-year mortality among PLEA
patients younger than 50 years compared with patients
50 years and older (12% vs 19%, respectively; P ¼ .126).
Established cardiovascular disease in patients with PAD
is strongly associated with long-term mortality. Clinical
CAD was present in 31% of our study patients at baseline,
which is comparable to a 29% prevalence of symptomatic
CAD reported by Harris et al15 in their series of 76 young
patients with premature PAD. Several other studies re-
ported symptomatic CAD in 20% of patients.9,11 However,
none of these investigators rigorously researched the
history of CAD. Our study estimates 5- and 10-year
mortality of 19% and 40%, respectively, in patients with
CAD at baseline. We also report substantial 5- and
10-year all-cause mortality of 15% and 27%, respectively,
in patients without documented CAD at ﬁrst evaluation.
Additional analysis of long-term mortality after exclusion
of patients with either prior malignancies or other morbid
systemic diseases showed a 5-year mortality of 17% and
14% in patients with or without CAD, respectively. Thus,
Fig 2. A, Kaplan-Meier survival estimates stratiﬁed by history of coronary artery disease (Hx CAD). B, Kaplan-Meier
survival estimates stratiﬁed by history of aspirin use. C, Kaplan-Meier survival estimates stratiﬁed by cancer status. D,
Kaplan-Meier survival estimates stratiﬁed by age <50 or $50 years. SE, Standard error.
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mortality even in the absence of established CAD at initial
evaluation. We believe this may result in part from uniden-
tiﬁed subclinical cardiovascular disease. Although the cause
of death was not available for all cases, the fact that 82% of
patients who died had either clinical cardiovascular disease
at baseline or documented cardiovascular events or revas-
cularizations during the follow-up period makes us believe
that the majority of deaths were related to severe cardiovas-
cular disease. Importantly, 5-year mortality observed in our
study corresponds with the 20% 5-year mortality reported
in young adults following myocardial infarction.19 Our
data support the notion that PAD also should be consid-
ered a CAD risk equivalent in younger individuals with
PLEA, which typically is associated with multiple tradi-
tional risk factors.
Another important predictor of cardiovascular mor-
tality in patients with PAD is its clinical severity assessed
by the severity of PAD symptoms, need for revasculariza-
tion, or amputation. Of these PAD characteristics, we
found amputations to be related to increased mortality.
Patients with prior amputation had an almost two-fold
increase in risk of death. Levy et al20 demonstrated that
PLEA is the main cause of amputations in young adults.
Valentine et al14 reported 37% 5-year mortality in patientsyounger than 50 years who had lower extremity amputa-
tions. Notably, patients with particularly common causes
of amputations, such as end-stage renal disease or diabetic
foot, were excluded from our study.
Preventive medical therapy plays a pivotal role in the
management of PAD. Smoking cessation, lipid-lowering
therapy with statins, antihypertensive therapy with utiliza-
tion of ACE inhibitors, and antiplatelet therapy are consid-
ered highly efﬁcacious in the reduction of cardiovascular
events and mortality in patients with PAD. Despite well-
established scientiﬁc evidence and publication of disease
management guidelines, PAD remains undertreated. Our
study provides information on the utilization of statin
therapy and the use of ACE inhibitors and aspirin at initial
evaluation. Overall, the baseline preventive medical therapy
actually was superior to that reported in the most recent
large series of individuals with PAD.17,21 More than 70%
of our study patients were taking a statin or aspirin, and
ACE inhibitor use was documented in almost half of the
patients. One of the most interesting and intriguing obser-
vations in the present study was the demonstration of
signiﬁcantly lower mortality in patients on aspirin therapy
at baseline. In a multivariable analysis, aspirin therapy was
associated with 55% risk reduction of all-cause mortality
during follow-up. Importantly, patients on aspirin therapy
Table IV. Causes of death in 108 patients
Cause of death N (%)
Cardiovascular 66 (61.1)
Malignancy 17 (15.7)
Pulmonary 7
Oropharyngeal 2
Gastrointestinal 1
Gynecologic 1
Miscellaneous 6
Other 21 (19.4)
Renal failure 4
Respiratory failure 4
Sepsis/infection 6
Cirrhosis 1
Gastrointestinal bleeding 1
Motor vehicle accident 1
Miscellaneous 4
Unknown 4 (3.7)
Fig 3. Kaplan-Meier survival estimates stratiﬁed by history of
coronary artery disease (Hx CAD), excluding patients with cancer
and systemic disease. SE, Standard error.
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and ACE inhibitor therapy compared with patients not
receiving aspirin. Also, greater use of aspirin was noted in
patients with established CAD and CeVD, which were
demonstrated to be linked with higher mortality. Based
on a Kaplan-Meier survival analysis, the beneﬁcial effect
of aspirin was demonstrated early during follow-up, with
2-year mortality of 4% in patients on aspirin at baseline
compared with 13% mortality in patients not receiving
aspirin therapy. Use of aspirin has been shown to be asso-
ciated with reduced risk of long-term mortality in elderly
patients.22,23 However, such a robust effect of aspirin on
reduction of all-cause mortality in younger individuals
with PLEA was never reported before. Comparing thesurvival plots of patients on aspirin vs those on no aspirin
at baseline with survival plots of patients with prior malig-
nancy vs those without prior malignancy, striking similari-
ties can be seen. Two-year mortality of patients without
aspirin or with prior malignancy was 13% and 11%, respec-
tively, and 5-year mortality was 25% and 24%, respectively.
Study limitations. Despite being the largest study
reported to date focusing on younger individuals with
severe premature PAD, several limitations warrant consid-
eration. First, this is an observational study, and our results
may be limited by selection bias, unmeasured confounders,
and residual confounding. Second, this was not a popula-
tion-based study. Our study group consisted of consecu-
tive patients who were referred to our vascular center.
Third, diagnosis of cardiovascular disease, cancer, and
systemic disease in many cases was based on patient self-
report and was not veriﬁed by review of outside records
in every case. Fourth, the data on the adequacy of blood
pressure, diabetes control, and lipid-lowering therapy were
not studied. Fifth, no data on ABI at the time of diagnosis
of PAD were available for the majority of patients; there-
fore, we were not able to study the association of ABI with
mortality in PLEA. Sixth, follow-up of the initial cohort
was incomplete, and we examined all-cause mortality, not
speciﬁcally cardiovascular mortality. Seventh, our ﬁndings
and conclusions are not generalizable to the entire PLEA
population; rather they reﬂect on patients treated in tertiary
vascular centers with added expertise, which is frequently
required in the case of younger adults with PAD.
CONCLUSIONS
Analysis of this large and diverse cohort of patients with
severe premature PAD resulting from large-vessel lower
extremity atherosclerosis provides important information
on the association between fairly easily ascertainable char-
acteristics and long-term mortality. Despite the relatively
high prevalence of prior malignancies or systemic diseases
at baseline, cardiovascular disease remains the main cause
of death in younger patients with PAD. Independent
predictors of all-cause mortality included systemic athero-
sclerosis, prior amputations, and lack of aspirin therapy at
baseline. Despite seemingly improved preventive medical
therapy at baseline, all-cause mortality remains high and
may indicate an aggressive nature of PLEA, the need for
identiﬁcation of additional nontraditional risk factors, and
greater utilization of preventive therapies.
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congratulate Dr Hamza Rana and his colleagues at Wake Forest
on an excellent presentation and thank them for forwarding
their manuscript to me in advance of the meeting. This work
is a collaboration between vascular surgery and vascular medi-
cine specialists and underscores the vital importance of risk
factor modiﬁcation and vigilant medical management of
patients with lower extremity peripheral arterial disease. In
a cohort of more than 500 young patients (deﬁned as <55
years of age) with premature lower extremity atherosclerosis,
they observed a 19% mortality rate during mean follow-up of
5.6 years. Two thirds of the observed mortalities were attribut-
able to cardiovascular causes, and predictors of overall mortality
included age, coronary disease, cerebrovascular disease, prior
amputation, cancer, and absence of aspirin therapy. The anal-
ysis is impressive in terms of cohort size and diversity, duration
of follow-up, and ﬁndings.
I have four questions:
1. Within the manuscript, you referenced 3- to 5-year mortality
rates of 17% to 32% in patients with premature lower extremity
atherosclerosis from previously published reports that are now
over thirty years old. When comparing those results with
your more current update, it seems that we have made little
or no impact on the mortality rates in this patient population
over a fairly long interval of time that has included some drastic
changes in approaches to cardiovascular risk reduction. Can
you comment on trends in the incidence of premature lower
extremity atherosclerosis over this same time frame, andwhether our current efforts should be focused on primary
versus secondary and tertiary prevention?
2. Your results demonstrate that, save for aspirin use, none of the
mortality risk factors you identiﬁed are modiﬁable. This leaves
the vascular surgeon or vascular medicine practitioner with
little guidance on how to change the care of these complex
patients to impact such a high mortality rate. Given this consid-
eration, did you consider evaluating more detailed surrogate
measures of medical management, such as blood pressure, lipid
or hemoglobin A1C levels, to see where greater focus is
needed?
3. You correctly identify your cohort of patients with premature
lower extremity atherosclerosis as one of the largest and most
diverse, in terms of gender and race/ethnicity, studied to date.
Given the rapidly growing body of evidence supporting signiﬁ-
cant gender- and race-speciﬁc risk proﬁles in patients with periph-
eral arterial disease, can you provide any additional details
regarding gender- and race-speciﬁc mortality? I would be partic-
ularly interested in the race and ethnicity makeup of the
nonwhite subgroup of patients, which accounted for 20% of
your cohort; what proportion of these patients were of African
American race or Hispanic/Latino ethnicity; and how their
mortality compared with white patients.
4. I was particularly impressed that 72% of your patient cohort were
smokers at baseline, suggesting that this is a very important risk
factor for development of premature lower extremity atheroscle-
rosis. Did you evaluate the incidence of smoking cessation over
the study period and whether this impactedmortality during the
JOURNAL OF VASCULAR SURGERY
36 Rana et al January 2013follow-up period? Can you describe your current approach to
smoking cessation in Winston-Salem, North Carolina?
I would like to thank the SAVS for allowing me to discuss this
important manuscript and again congratulate the authors on their
outstanding work.
Dr Hamza Rana. Thank you so much, Dr Corriere, for your
excellent questions and discussion. I will answer your second ques-
tion ﬁrst, which is regarding the risk factors. All of the available
predictors in our analysis that were included were collected at
the time of the initial evaluation of vascular care, so we did not
look at the intensity of their control or the duration of their risk
factors in this analysis. I completely agree with you that each of
these traditional risk factors has a continuous dose-dependent
effect on the cardiovascular risk, factors that we did not have avail-
able in our study, such as blood pressure control, lipid level, and
blood glucose control. Thus it is one of the limitations of our
study. The second factor that could have contributed to this
ﬁnding is that we looked at all-cause mortality, not the cardiovas-
cular mortality speciﬁcally, but we do plan to look at it in the near
future and report it as a separate analysis. In response to your ﬁrst
question regarding the incidence and prevention strategies, there
are no data from the large population-based studies on the inci-
dence of premature lower extremity atherosclerosis. However,
previous small studies have reported the incidence anywhere
between 2% and 5%, or up to 7% in some studies. In our anecdotal
experience at Wake Forest, we are seeing an increasing number of
patients with premature lower extremity atherosclerosis every year.
With the growing awareness of PAD, I believe that we will see
more and more patients with premature lower extremity athero-
sclerosis. In response to the prevention strategies, I believe all
forms of the prevention strategies are essential, but we should
focus on the primary prevention because it is important. As we
see from the study, premature lower extremity atherosclerosis
has such a high mortality (9- to 10-fold higher than the expected
mortality for the same age), and the majority of these patients
interestingly were on disability at the time of initial evaluation.
Therefore, we need to focus on the primary prevention. Our aimshould be to identify these at-risk populations very early on,
perhaps in their twenties or early thirties, and to initiate and sustain
the treatment more consistently in those populations at risk. In
response to the secondary prevention, I think we need to recog-
nize premature lower extremity atherosclerosis as a coronary artery
disease risk equivalent as these patients remain untreated so that all
of these patients are automatically eligible to get aggressive risk
factor modiﬁcation. There is enormous large evidence base that
can guide us for the prevention strategies. As you saw in our anal-
ysis of aspirin therapy, the patients on aspirin at the time of initial
evaluation had a 55% lower risk of mortality. In response to your
third question about gender and race, for the nonwhite race in
our analysis, almost all of the patients were African Americans.
In our experience, African Americans mostly have infrainguinal
disease, and diabetes was more common in that race. In our multi-
variable model, race and gender were not independent predictors
of mortality. We had 111 patients as nonwhite. There were 26
deaths during the follow-up period, which is close to 24%. In
response to your last question about smoking cessation, as you
have pointed out, 72% of the patients are current smokers;
however, in the data that was not reported here, the patients
who ever smoked were 96% or 97%, so we could assume that we
have made some contribution there as far as the smoking cessation
was concerned. Again, we just looked at predictors at initial evalu-
ation, so we did not look at any intervention. Thus, I do not have
the data on smoking cessation in terms of how it relates as
a predictor of mortality. In terms of what we do in Winston-Salem
for smoking cessation, we do address the smoking cessation at each
visit and we follow the clinical guideline by the United States
Public Health Services which is the 5 A’s: Ask if they smoke, which
mostly is yes; Advise to quit smoking; Assess for readiness; Assist
with a plan that is behavioral therapy where we encourage them
to quit smoking, nicotine replacement therapies, and pharmaco-
logical therapies as well; and Arrange for follow-up, where we try
to discuss smoking cessation at each follow-up visit. We do have
available to us at Wake Forest a smoking cessation clinic, which
is run by the family practitioners whom we utilize.
